David G Parkes

Summary

Affiliation: Amylin Pharmaceuticals
Country: USA

Publications

  1. doi request reprint Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
    David G Parkes
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Expert Opin Drug Discov 8:219-44. 2013
  2. doi request reprint Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin?
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, CA 92121, United States
    Physiol Behav 100:187-95. 2010
  3. doi request reprint Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Am J Physiol Gastrointest Liver Physiol 302:G762-72. 2012
  4. doi request reprint Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Endocrinology 149:5679-87. 2008
  5. doi request reprint Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, California, USA
    Obesity (Silver Spring) 18:21-6. 2010
  6. doi request reprint Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Endocrinology 151:5657-68. 2010
  7. doi request reprint Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration
    Bronislava R Gedulin
    Amylin Pharmaceuticals, Inc 9360 Towne Centre Dr, Ste 110, San Diego, CA 92121, United States
    Int J Pharm 356:231-8. 2008
  8. pmc The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
    Que Liu
    Amylin Pharmaceuticals, Inc, San Diego, CA, USA
    Cardiovasc Diabetol 9:32. 2010
  9. ncbi request reprint Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight
    Bronislava R Gedulin
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, Suite 110, San Diego, California 92121, USA
    Endocrinology 146:2069-76. 2005
  10. doi request reprint Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models
    Jason R Clapper
    Amylin Pharmaceuticals, LLC, San Diego, CA 92121, USA
    Eur J Pharmacol 698:292-8. 2013

Collaborators

Detail Information

Publications22

  1. doi request reprint Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
    David G Parkes
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Expert Opin Drug Discov 8:219-44. 2013
    ..In clinical trials, both exenatide formulations reduced hyperglycemia in patients with type 2 diabetes mellitus (T2DM) and were associated with weight loss...
  2. doi request reprint Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin?
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, CA 92121, United States
    Physiol Behav 100:187-95. 2010
    ....
  3. doi request reprint Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Am J Physiol Gastrointest Liver Physiol 302:G762-72. 2012
    ..Our pharmacological data further support the clinical evaluation of the utility of GLP-1R agonists for treatment of NASH...
  4. doi request reprint Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Endocrinology 149:5679-87. 2008
    ..We conclude that amylin/leptin interact synergistically to reduce body weight and adiposity in diet-induced obese rodents through a number of anorexigenic and metabolic effects...
  5. doi request reprint Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, California, USA
    Obesity (Silver Spring) 18:21-6. 2010
    ....
  6. doi request reprint Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Endocrinology 151:5657-68. 2010
    ..These findings support the clinical investigation of amylin in low estradiol (e.g. postmenopausal) states...
  7. doi request reprint Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration
    Bronislava R Gedulin
    Amylin Pharmaceuticals, Inc 9360 Towne Centre Dr, Ste 110, San Diego, CA 92121, United States
    Int J Pharm 356:231-8. 2008
    ..Despite little optimization of the delivery formulation, exenatide bioavailability compared favorable to that of several commercially available bioactive peptides...
  8. pmc The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
    Que Liu
    Amylin Pharmaceuticals, Inc, San Diego, CA, USA
    Cardiovasc Diabetol 9:32. 2010
    ..Hypothetically, chronic AC3174 treatment could attenuate salt-induced hypertension, cardiac morbidity, insulin resistance, and renal dysfunction in Dahl salt-sensitive (DSS) rats...
  9. ncbi request reprint Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight
    Bronislava R Gedulin
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, Suite 110, San Diego, California 92121, USA
    Endocrinology 146:2069-76. 2005
    ....
  10. doi request reprint Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models
    Jason R Clapper
    Amylin Pharmaceuticals, LLC, San Diego, CA 92121, USA
    Eur J Pharmacol 698:292-8. 2013
    ..These findings support the strategy of combined amylin agonism with opioid and catecholaminergic signaling systems for the treatment of obesity...
  11. ncbi request reprint Biological activity of AC3174, a peptide analog of exendin-4
    Diane M Hargrove
    Amylin Pharmaceuticals Inc 9360 Towne Centre Drive, San Diego, CA 92121, United States
    Regul Pept 141:113-9. 2007
    ..In summary, AC3174 is an analog of exenatide that binds to the GLP-1 receptor in vitro and shares many of the biological and glucoregulatory activities of exenatide and GLP-1 in vivo...
  12. pmc Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents
    Krystyna Tatarkiewicz
    Amylin Pharmaceuticals, San Diego, CA, USA
    Am J Physiol Endocrinol Metab 299:E1076-86. 2010
    ..In conclusion, exenatide did not modify plasma amylase and lipase concentrations in rodents without pancreatitis and improved chemically induced pancreatitis in normal and diabetic rodents...
  13. doi request reprint Insights into amylin-leptin synergy
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Trends Endocrinol Metab 21:473-9. 2010
    ..Understanding how amylin agonism improves leptin function could point to general therapeutic strategies for combating leptin resistance and associated obesity...
  14. doi request reprint "Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Brain Res 1350:86-94. 2010
    ..Finally, we briefly discuss what the future landscape of neurohormonal anti-obesity combinations may hold...
  15. doi request reprint Mechanisms of amylin/leptin synergy in rodent models
    Victoria F Turek
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, California 92121, USA
    Endocrinology 151:143-52. 2010
    ....
  16. pmc Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 105:7257-62. 2008
    ....
  17. doi request reprint Exenatide improves hypertension in a rat model of the metabolic syndrome
    Kevin D Laugero
    Amylin Pharmaceuticals Inc, San Diego, California, USA
    Metab Syndr Relat Disord 7:327-34. 2009
    ..However, there are limited studies testing the chronic effects of these peptides on arterial pressure and no reports showing the effects of these peptides to reverse hypertension in the context of the metabolic syndrome...
  18. pmc GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc San Diego, CA, USA
    Br J Pharmacol 166:121-36. 2012
    ..Finally, the future of GLP-1- and amylin agonist-based therapeutics is discussed...
  19. pmc Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
    Que Liu
    Amylin Pharmaceuticals Inc, San Diego, CA 92121, USA
    Cardiovasc Diabetol 9:76. 2010
    ....
  20. ncbi request reprint Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity
    Jonathan D Roth
    Amylin Pharmaceuticals Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Endocrinology 148:6054-61. 2007
    ..Collectively, these observations highlight the importance of studying peptide hormones in combination and suggest that integrated neurohormonal approaches may hold promise as treatments for obesity...
  21. ncbi request reprint Investigation of exenatide elimination and its in vivo and in vitro degradation
    Kathrin Copley
    Amylin Pharmaceuticals, Inc 9360 Towne Centre Dr, Ste 110, San Diego, CA 92121, USA
    Curr Drug Metab 7:367-74. 2006
    ..Exenatide (15-39) and (16-39) had moderate-to-weak antagonist activity compared with the known antagonist, exenatide (9-39). In conclusion, the kidney appears to be the primary route of elimination and degradation of exenatide...
  22. ncbi request reprint Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
    Loretta L Nielsen
    Amylin Pharmaceuticals Inc, 9360 Town Centre Dr Ste 110, San Diego, CA 92121, USA
    Regul Pept 117:77-88. 2004
    ....